Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study

Table 5 Multivariate Cox regression analysis for hepatocellular carcinoma and death/transplantation among the sustained virologic response cohort

Variable	Hepatocellular carcinoma		Death/transplantation
	aHR (95%CI)	P value	aHR (95%CI)	P value
IBT-SVR group	Reference	-	Reference	-
DAA-SVR group	2.03 (0.76-5.43)	0.16	1.38 (0.55-3.49)	0.494
Age, yr	1.05 (1.01-1.10)	0.025	-	-
Male sex	2.89 (0.97-8.61)	0.057	-	-
HCV genotype			-	–
2	Reference	-
1	3.02 (1.18-7.68)	0.021
Cirrhosis	3.18 (1.33-7.68)	0.009	2.97 (1.42-6.20)	0.004
Ever smoker	0.72 (0.26-1.99)	0.545	-	-
Alcohol consumption			-	-
None	Reference	-
Social	2.62 (0.92-7.60)	0.072
Significant	2.51 (0.71-8.82)	0.152
BMI, kg/m2	-	-	-	-
Diabetes mellitus	1.03 (0.42-2.52)	0.952	2.16 (0.98-4.78)	0.057
Albumin, g/dL	0.53 (0.19-1.49)	0.228	-	-
Total bilirubin, mg/dL	-	-	-	-
PT, INR	4.12 (0.89-19.17)	0.071	5.27 (1.01-27.53)	0.049
AFP, log10 ng/dL	1.07 (0.49-2.34)	0.858	-	-

Total number of patients, 1250; number of hepatocellular carcinomas, 30; number of deaths, 7; number of transplantations, 3. AFP: Alpha-feto protein; aHR: Adjusted hazard ratio; BMI: Body mass index; CI: Confidence interval; DAA: Direct acting antivirals; HCV: Hepatitis C virus; IBT: Interferon-based therapy; PT: Prothrombin time; SVR: Sustained virologic response.